Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Stock

Equities

301126

CNE1000054V3

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-06-02 pm EDT 5-day change 1st Jan Change
9.42 CNY -3.29% Intraday chart for Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd -3.38% -27.71%
Sales 2022 3.29B 455M Sales 2023 3.9B 539M Capitalization 2.69B 372M
Net income 2022 51M 7.04M Net income 2023 34M 4.7M EV / Sales 2022 1.23 x
Net Debt 2022 967M 134M Net Debt 2023 1.92B 266M EV / Sales 2023 1.18 x
P/E ratio 2022
59.6 x
P/E ratio 2023
76.6 x
Employees 3,461
Yield 2022
0.19%
Yield 2023
0.31%
Free-Float 37.57%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Cash Dividend for 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 119.999994 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd signed the share acquisition agreement to acquire 51% stake in Shanxi Simaile Pharmaceutical Chain Co., Ltd. from Yang Jinjiang, Liu Hongming for approximately CNY 330 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million. CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Implements Final Cash Dividend of A Shares for the Year 2022, Payable on June 12, 2023 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Final Cash Dividend for 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd cancelled the transaction announced on May 18, 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd announced that it expects to receive CNY 300 million in funding CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Proposes Final Cash Dividend for the Year 2022 CI
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news
1 day-3.29%
1 week-3.38%
Current month-3.29%
1 month-1.26%
3 months+3.86%
6 months-31.19%
Current year-27.71%
More quotes
1 week
9.30
Extreme 9.3
9.89
1 month
9.30
Extreme 9.3
12.35
Current year
6.61
Extreme 6.61
14.39
1 year
6.61
Extreme 6.61
16.85
3 years
6.61
Extreme 6.61
36.84
5 years
6.61
Extreme 6.61
36.84
10 years
6.61
Extreme 6.61
36.84
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 17-04-15
Chairman 53 02-06-30
Chairman 59 02-09-30
Members of the board TitleAgeSince
Director/Board Member 51 19-11-13
Director/Board Member 54 20-09-09
Chairman 59 02-09-30
More insiders
Date Price Change Volume
24-06-02 9.42 -3.29% 4 280 800
24-05-31 9.74 +0.62% 3,500,000
24-05-30 9.68 -0.92% 3,621,500
24-05-29 9.77 +0.21% 3,339,300
24-05-28 9.75 -1.12% 3,579,600

End-of-day quote Shenzhen S.E., June 02, 2024

More quotes
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
More about the company
  1. Stock Market
  2. Equities
  3. 301126 Stock